Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Cardinal Health's specialty growth, strong cash flow and expanding higher-margin businesses are boosting earnings momentum despite IRA and GMPD risks.
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
April 2026 delivered another major milestone for the portfolio. We posted an insane 80% year-over-year increase. In April 2026, I received $1,742.78 in dividend income compared to $968.18 in April 2025. Looking beyond just April, the full 2026 dividend income picture continues to trend dramatically ahead of 2025. The portfolio is producing significantly more cash flow through the first four months of the year.
Cardinal Health is expanding beyond drug distribution into specialty care, logistics and nuclear medicine, deepening its role in US healthcare infrastructure.
Kiplinger's Personal Finance May 2026 letter makes it clear that if you are looking for yield, the door is wide open across the entire risk spectrum. We are seeing a massive spread, with opportunities ranging from stable 3% municipal bonds to 13% for those willing to get aggressive with business development companies. This is unfolding... Kiplinger's May 2026 Letter Says Yields From 3% to 13% Are Available Right Now Despite Iran War Uncertainty
CAH shares are down 9.4% YTD, but strong specialty drug growth, rising earnings estimates and a raised outlook may signal upside.
Roughly a year ago, 24/7 Wall St. ran a piece titled Forget UnitedHealth.
Cardinal Health, Inc. (CAH) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Cardinal Health's CAH Pharmaceutical & Specialty Solutions segment continues to be the primary engine of enterprise growth, delivering another standout quarter in the third quarter of fiscal 2026. Segment revenues climbed 19% to approximately $61 billion, while segment profit increased 29%, underscoring the segment's growing importance to Cardinal Health's earnings profile.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
The heavy selling pressure might have exhausted for Cardinal (CAH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.
Cardinal (CAH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cardinal (CAH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
As expected, Apple focused on share buybacks, increasing its share repurchase authorization by $100 billion while announcing a 4% dividend increase. Looking forward to the first half of May, Cardinal Health is expected to announce a modest 1–3% dividend increase, maintaining its pattern of minimal payout growth despite strong EPS expansion. Strong EPS growth—9% in 2025 and 23–25% projected for 2026—has not translated into higher dividend increases for CAH, as management prioritizes repurchases.